{"id":"ropinirole-ir","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dyskinesia"}]},"_chembl":{"chemblId":"CHEMBL1200411","moleculeType":"Small molecule","molecularWeight":"296.84"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ropinirole IR is a dopamine agonist that directly stimulates dopamine receptors in the brain, mimicking the action of dopamine and helping to alleviate symptoms of Parkinson's disease, such as tremors, stiffness, and bradykinesia. This is in contrast to levodopa, which is converted to dopamine in the brain. By directly activating dopamine receptors, ropinirole IR can provide more consistent and predictable results.","oneSentence":"Ropinirole IR works by activating dopamine receptors in the brain, increasing dopamine levels and helping to alleviate symptoms of Parkinson's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:37.392Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Restless legs syndrome"}]},"trialDetails":[{"nctId":"NCT00256854","phase":"PHASE3","title":"Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-14","conditions":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","enrollment":135},{"nctId":"NCT00996944","phase":"PHASE2","title":"Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-30","conditions":"Restless Legs Syndrome","enrollment":34},{"nctId":"NCT00140712","phase":"PHASE1","title":"Ropinirole Tablets In Young Patients With Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-10","conditions":"Restless Legs Syndrome","enrollment":9},{"nctId":"NCT00331149","phase":"PHASE3","title":"A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06-20","conditions":"Parkinson Disease","enrollment":343},{"nctId":"NCT00632736","phase":"PHASE3","title":"An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-02","conditions":"Parkinson Disease, Parkinson's Disease","enrollment":419},{"nctId":"NCT00329602","phase":"PHASE4","title":"Long-term Study Of Ropinirole In Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03","conditions":"Restless Legs Syndrome","enrollment":404},{"nctId":"NCT00823836","phase":"PHASE3","title":"Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Parkinson Disease","enrollment":302},{"nctId":"NCT00314860","phase":"PHASE3","title":"RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02","conditions":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","enrollment":568},{"nctId":"NCT00144300","phase":"PHASE4","title":"Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-01","conditions":"Parkinson Disease","enrollment":246},{"nctId":"NCT00650104","phase":"PHASE3","title":"Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-05","conditions":"Parkinson Disease","enrollment":76},{"nctId":"NCT00485069","phase":"PHASE4","title":"REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Parkinson Disease, Parkinson's Disease","enrollment":123}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ropinirole IR","genericName":"ropinirole IR","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ropinirole IR works by activating dopamine receptors in the brain, increasing dopamine levels and helping to alleviate symptoms of Parkinson's disease. Used for Parkinson's disease, Restless legs syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}